Shaamil Karim
Founder of Atlas Discovery, AI-native pharma company
Company
Shaamil Karim is listed as a founder of Atlas Discovery. AI-native pharma company
Founder traction evidence
Public posts and activity attributed directly to this founder.
- X
Nine out of ten drugs fail in clinical trials because we can’t predict how a patient will respond.
Nine out of ten drugs fail in clinical trials because we can’t predict how a patient will respond. We backtested our foundation model of patient biology on multiple clinical trials in Cancer and Autoimmune diseases and successfully separated responders vs non-responders 70-90% of
- LinkedIn
Founder says he started Atlas Discovery. Post says Atlas Discovery raised funding from Y Combinator.
Founder says he started Atlas Discovery. Post says Atlas Discovery raised funding from Y Combinator.
- X
Today we're excited to announce our partnership with Alliance to Cure.
Today we're excited to announce our partnership with Alliance to Cure. Our biomedical research agents found a novel drug repurposing candidate for Cerebral Cavernous Malformation and the foundation is now running preclinical tests on it!
- X
We trained a foundation model of patient biology that predicts drug response from a single biopsy before treatment.
We trained a foundation model of patient biology that predicts drug response from a single biopsy before treatment. As a case study, we tested on a phase 3 trial of ustekinumab in IBD and get a 0.76 AUROC, enough to run it with ~450 fewer patients at the same statistical power....
- X
Super well written. Thanks @agupta!
Super well written. Thanks @agupta!
- X
Excited to share our paper at @icmlconf genbio right now.
Excited to share our paper at @icmlconf genbio right now. We ablate the core design choices in latent perturbation prediction and then tested the model on a real-world out-of-distribution target discovery task from Pfizer, achieving SOTA results. Read more from @splicewiring!
- X
Highly recommend this podcast.
Highly recommend this podcast. @BenjamineYLiu does a good job explaining the thesis that drug design is becoming commoditized and drug development will be the bottleneck. Casual targets of disease are also an issue, but real-world data can help build better predictive models.
- X
If you’re interested in research, joining this team could be one of the highest slopes of learning for you!
If you’re interested in research, joining this team could be one of the highest slopes of learning for you!